Endocrinology, Vol 126, 110-117, Copyright © 1990 by Endocrine Society

ARTICLES

Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro

EY Lui, SL Asa, DJ Drucker, YC Lee and PL Brubaker
Department of Physiology, University of Toronto, Ontario, Canada.

Proglucagon-derived peptides are localized in pancreas, intestine, and the nervous system. We have examined the ontogeny of glucagon and related peptides in developing rat hypothalamus and have developed a fetal rat hypothalamic cell culture model to study the synthesis and secretion of these peptides in cells of neural origin. Fetal rat hypothalamus (19-21 day gestation) was found to contain glucagon-like immunoreactive (GLI) peptides including glucagon. The relative amounts of two of the GLI peptides (glicentin and oxyntomodulin) increased with development such that adult hypothalamus contained a predominance of these peptides over glucagon. The ratio of GLI peptides to glucagon increased from 2.6 +/- 0.5 in fetus to 46 +/- 11 in adult (P less than 0.001). When fetal rat hypothalamic cells (FRHC) were placed into primary culture for 7 days, the presence of neurons, glial cells, and glucagon-containing cells was detected by immunohistochemical staining. Analysis of proglucagon gene expression in FRHC cultures by Northern blotting demonstrated the presence of a single proglucagon messenger RNA (mRNA) transcript identical in size and sequence to that detected in fetal pancreas and intestine. RNase protection analysis of RNA from FRHC cultures, brainstem, and intestine confirmed that the proglucagon mRNA transcripts present in these three tissues were identical. Analysis of FRHC content of GLI peptides and immunoreactive glucagon demonstrated that peptide levels were not significantly different from those of whole fetal rat hypothalamus, and did not vary significantly throughout 2 weeks in culture. FRHC cultures were found to contain substantial amounts of glucagon after 1 week of culture. Release of the GLI peptides on day 7 of culture was increased 3-fold (P less than 0.001) by treatment of FRHC for 1 h with 5 mM (Bu)2cAMP. Rat hypothalamus therefore appears to undergo unique changes in posttranslational processing of proglucagon during development. Primary cultures of FRHC thus provide a promising in vitro model to study the molecular control of proglucagon biosynthesis and GLI peptide secretion in the brain.

This article has been cited by other articles:

				L R Ranganath Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 J. Clin. Pathol., April 1, 2008; 61(4): 401 - 409. [Abstract] [Full Text] [PDF]

				E. T. Parlevliet, A. C. Heijboer, J. P. Schroder-van der Elst, L. M. Havekes, J. A. Romijn, H. Pijl, and E. P. M. Corssmit Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E142 - E147. [Abstract] [Full Text] [PDF]

				A. Dey, G. M. Lipkind, Y. Rouille, C. Norrbom, J. Stein, C. Zhang, R. Carroll, and D. F. Steiner Significance of Prohormone Convertase 2, PC2, Mediated Initial Cleavage at the Proglucagon Interdomain Site, Lys70-Arg71, to Generate Glucagon Endocrinology, February 1, 2005; 146(2): 713 - 727. [Abstract] [Full Text] [PDF]

				J. A. Lovshin, Q. Huang, R. Seaberg, P. L. Brubaker, and D. J. Drucker Extrahypothalamic Expression of the Glucagon-Like Peptide-2 Receptor Is Coupled to Reduction of Glutamate-Induced Cell Death in Cultured Hippocampal Cells Endocrinology, July 1, 2004; 145(7): 3495 - 3506. [Abstract] [Full Text] [PDF]

				D. J. Drucker Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis Mol. Endocrinol., February 1, 2003; 17(2): 161 - 171. [Abstract] [Full Text] [PDF]

				C. L. Dakin, C. J. Small, A. J. Park, A. Seth, M. A. Ghatei, and S. R. Bloom Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1173 - E1177. [Abstract] [Full Text] [PDF]

				J. Lovshin, B. Yusta, I. Iliopoulos, A. Migirdicyan, L. Dableh, P. L. Brubaker, and D. J. Drucker Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine Endocrinology, November 1, 2000; 141(11): 4194 - 4201. [Abstract] [Full Text] [PDF]

				N. J. MacLusky, S. Cook, L. Scrocchi, J. Shin, J. Kim, F. Vaccarino, S. L. Asa, and D. J. Drucker Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling Endocrinology, February 1, 2000; 141(2): 752 - 762. [Abstract] [Full Text] [PDF]

				T. J. Kieffer and J. Francis Habener The Glucagon-Like Peptides Endocr. Rev., December 1, 1999; 20(6): 876 - 913. [Abstract] [Full Text]

				P. L. Brubaker, K. A. Gronau, S. L. Asa, and G. R. Greenberg Nutrient and Peptide Regulation of Somatostatin-28 Secretion from Intestinal Cultures Endocrinology, January 1, 1998; 139(1): 148 - 155. [Abstract] [Full Text] [PDF]

				M. E. Rothenberg, C. D. Eilertson, K. Klein, Y. Zhou, I. Lindberg, J. K. McDonald, R. B. Mackin, and B. D. Noe Processing of Mouse Proglucagon by Recombinant Prohormone Convertase 1 and Immunopurified Prohormone Convertase 2 in Vitro J. Biol. Chem., April 28, 1995; 270(17): 10136 - 10146. [Abstract] [Full Text] [PDF]